Zymeworks Inc. (NYSE:ZYME) traded at a new 52-week low today of $27.25. This new low was reached on below average trading volume as 250,000 shares traded hands, while the average 30-day volume is approximately 363,000 shares.
Zymeworks Inc is a clinical-stage company. It is dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. The company’s product candidate, ZW25, is a bispecific (dual-targeting) antibody being evaluated in an adaptive Phase 1 clinical trial, targeting two distinct domains of the human epidermal growth factor receptor 2, or HER2. Its design enables ZW25 to address patient populations with all levels of HER2 expression, including those with low to intermediate HER2-expressing tumors, who are otherwise limited to chemotherapy or hormone therapy.
Potential upside of 10.3% exists for Zymeworks Inc., based on a current level of $27.52 and analysts’ average consensus price target of $30.34.
In the past 52 weeks, shares of Zymeworks Inc. have traded between the current low of $27.25 and a high of $59.03 and is now at $27.52.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer